Omeprazole Market Analysis

  • Report ID: 2477
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

Omeprazole Market Analysis

Dosage Form (Capsule, Tablet, Powder)

The capsule segment is expected to propel the omeprazole market growth in the forecast period. The capsule segment is expected to occupy 52% of the largest market share by 2036. Additionally, the capsule is expected to cross 1800 Million by the end of 2036. The tablets are easy to handle and inexpensive. Also, 2020 will see a 24% increase in total medication use to 4.5 trillion doses. More than half of the world's population will take more than one dose of medication per person per day, up from one-third in 2005, with India, China, Brazil, and Indonesia leading the way. This may result in the expansion of industry growth.

Indication (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux, Erosive Esophagitis)

The duodenal ulcer category is expected to drive market growth. This category was leading the market in 2019 as well. Duodenal ulcers are most commonly observed in the age groups of 25-55 years. With age, the incidence of peptic ulcer increased to a peak of 28.8% in the 5th decade of life. Duodenal ulcers are thought to affect 5 to 15% of people in the West, according to numerous studies that have assessed their prevalence. These factors are driving the growth of this segment. 

Our in-depth analysis of the global market includes the following segments:

     Dosage Form

  • Capsule
  • Tablet
  • Powder

     Distribution Channel

  • Hospital
  • Retail
  • Online

     Indication

  • Duodenal Ulcer
  • Gastric Ulcer
  • Gastroesophageal Reflux
  • Erosive Esophagitis
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2477
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of omeprazole is estimated at USD 1.12 Billion.

The omeprazole market size was valued at USD 1.06 Billion in 2023 and is expected to cross USD 2.38 Billion by the end of 2036, expanding at more than 6.4% CAGR during the forecast period i.e., between 2024-2036. Increasing cases of gastroesophageal reflux, increasing awareness among people, and increasing prevalence of duodenal ulcers.

Asia Pacific industry will hold a share of 28.6% by 2036, driven by greater awareness amongst target audiences about treating this condition, growing incidences, and intensified focus of key players to increase their product portfolio in the region.

Boehringer Ingelheim, AstraZeneca Plc., Azurity Pharma, Perrigo Company Plc., Salix pharmaceuticals
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample